NEW YORK, May 10, 2017 /PRNewswire/ --
Stock-Callers.com has been issued research reports on Steris PLC (NYSE: STE), NuVasive Inc. (NASDAQ: NUVA), Smith & Nephew PLC (NYSE: SNN), and Nevro Corp. (NYSE: NVRO). Most of the time, Medical Appliances and Equipment companies are structured as corporations. They also tend to offer below-average dividend yields when compared to the wider market. Register now and get full and free access to our downloadable research reports on these stocks at:
On Tuesday, shares in Leicester, the UK headquartered Steris PLC recorded a trading volume of 930,726 shares, which was above their three months average volume of 480,170 shares. The stock ended at $75.92, up 0.82% from the last trading session. The Company's shares have gained 8.61% in the last one month, 14.94% over the previous three months, and 13.11% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 7.80% and 9.69%, respectively. Furthermore, shares of Steris, which develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide, have a Relative Strength Index (RSI) of 78.09.
On May 03rd, 2017, research firm KeyBanc Capital Markets upgraded the Company's stock rating from 'Sector Weight' to 'Overweight'. Access our complete research report on STE for free at:
San Diego, California headquartered NuVasive Inc.'s stock finished yesterday's session 1.50% lower at $71.16. A total volume of 764,162 shares was traded, which was above their three months average volume of 581,470 shares. The Company's shares have gained 5.64% on an YTD basis. The stock is trading above its 200-day moving average by 4.50%. Furthermore, shares of NuVasive, which develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery, have an RSI of 38.43.
On April 25th, 2017, NuVasive announced financial results for Q1 ended March 31st, 2017. Revenue was $250 million; GAAP operating profit margin was 9.3%; non-GAAP operating profit margin was 14.1%; GAAP diluted earnings per share (EPS) was $0.22; and non-GAAP diluted EPS was $0.38. Additionally, the Company expanded its existing revolving line of credit from $150 million up to $500 million during Q1 2017. The complimentary research report on NUVA can be downloaded at:
Smith & Nephew
At the close of trading on Tuesday, shares in London, the UK headquartered Smith & Nephew PLC rose 0.59%, ending the day at $33.95. The stock recorded a trading volume of 458,287 shares. The Company's shares have advanced 9.16% in the last one month, 12.23% in the previous three months, and 14.21% since the start of this year. The stock is trading 8.03% and 10.47% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Smith & Nephew, which designs, develops, and sells medical devices worldwide, have an RSI of 73.30.
On May 04th, 2017, Smith & Nephew welcomed the publication of a new research paper showing how pressure ulcers, when treated with Collagenase SANTYL Ointment, achieve faster rates of granulation and epithelialization when compared against medicinal honey treatment. In a retrospective study of 787 patients, those who received SANTYL treatment on 1,034 pressure ulcers were 38% more likely to achieve 100% granulation, and 47% more likely to achieve epithelialization at one year when compared to medicinal honey treatment. Register for free on Stock-Callers.com and get access to the latest PDF format report on SNN at:
Redwood City, California headquartered Nevro Corp.'s shares ended the day 12.48% lower at $75.53. A total volume of 6.06 million shares was traded, which was above their three months average volume of 396,760 shares. The stock has gained 3.95% on an YTD basis. The Company's shares are trading 15.83% below their 200-day moving average. Additionally, shares of Nevro, which focuses on providing products for the patients suffering from chronic pain in the US and internationally, have an RSI of 25.99.
On May 02nd, 2017, Nevro announced that its management will be presenting at the Bank of America Merrill Lynch 2017 Health Care Conference on Tuesday, May 16th, 2017, in Las Vegas. Management is scheduled to present at 10:40 a.m. PT. The presentation will be accessible via a live audio webcast, accessible under the "Investors" section of the Company's website. Download your free research report on NVRO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA